ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CCNA2	890	12073048	Endometrial adenocarcinoma; Endometrial hyperplasia	-	-	-	15 (5 proliferative+ 5 secertory + 5 atrophic)	23 (endometrial hyperplasia); 112 (endometrial adenocarcinoma)	30 to 83 (pateint); 26 to 51 (normal)	-	Kitasato University Hospital	I (n=75); II (n=11); III (n=24); IV (n=2)	1 (n=48); 2 (n=46); 3 (n=15)	[1] Cyclin A expression was involved in the progression to malignancy of the endometrium and was correlated with proliferative activity and prognostic features including histological grade; without coexisting endometrial hyperplasia and LVSI. [2] mmunohistochemistry showed that the nuclei of the cells were positive for cyclin A. In normal endometrium; only proliferative phase was focally positive for cyclin A. Cyclin A was also positive for endometrial hyperplasia. Its expression in hyperplasia was significantly more frequent than that of proliferative phase and less than that of endometrioid adenocarcinoma. The labeling index (LI) of cyclin A in endometrioid adenocarcinoma was 16.3+/-6.9 in well-differentiated; 18.3+/-8.8 in moderately differentiated; and 30.2+/-11.8 in poorly differentiated adenocarcinoma; respectively. Cyclin A expression increased significantly more in high histological grades. [3] Cyclin A expression was significantly associated with carcinoma without coexisting endometrial hyperplasia and lymphovascular space involvement (LVSI); but not with FIGO stage; myometrial invasion; lymph node metastasis; estrogen receptor; progesterone receptor; and menopause as well as recurrence.	Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.	Journal of Cancer Research and Clinical Oncology	128(6):307-12.	2002